Systematic drug susceptibility testing: a necessary component of the 'DOTS plus' strategy?

Editorial

P J Grosset. Int J Tuberc Lung Dis. 1999 Jul.

. 1999 Jul;3(7):549-50.

No abstract available

Comment on

Drug susceptibility testing of Mycobacterium tuberculosis: a neglected problem at the turn of the century.
Heifets LB, Cangelosi GA. Heifets LB, et al. Int J Tuberc Lung Dis. 1999 Jul;3(7):564-81. Int J Tuberc Lung Dis. 1999. PMID: 10423219 Review.

Rational 'DOTS plus' for the control of MDR-TB.
Espinal MA, Dye C, Raviglione M, Kochi A. Espinal MA, et al. Int J Tuberc Lung Dis. 1999 Jul;3(7):561-3. Int J Tuberc Lung Dis. 1999. PMID: 10423218 Review. No abstract available.
Surveillance of Mycobacterium tuberculosis susceptibility to second-line drugs in Hong Kong, 1995-2002, after the implementation of DOTS-plus.
Kam KM, Yip CW. Kam KM, et al. Int J Tuberc Lung Dis. 2004 Jun;8(6):760-6. Int J Tuberc Lung Dis. 2004. PMID: 15182147
New generation methods for drug susceptibility testing for tuberculosis.
Katoch VM. Katoch VM. Indian J Tuberc. 2008 Apr;55(2):61-3. Indian J Tuberc. 2008. PMID: 18516820 No abstract available.
Study of primary drug resistance of Mycobacterium tuberculosis from two hospitals in Tenerife, Canary Islands, Spain (1990-1997).
Lecuona M, Alvarez R, Quintero J, Torres A, Hernández AM, Montesinos I, Sierra A. Lecuona M, et al. Int J Tuberc Lung Dis. 2000 Feb;4(2):186-7. Int J Tuberc Lung Dis. 2000. PMID: 10694101 Clinical Trial. No abstract available.
Drug susceptibility testing of Mycobacterium tuberculosis: a neglected problem at the turn of the century.
Heifets LB, Cangelosi GA. Heifets LB, et al. Int J Tuberc Lung Dis. 1999 Jul;3(7):564-81. Int J Tuberc Lung Dis. 1999. PMID: 10423219 Review.

To Test or Not to Test? Ending the Age-Old Debate for Drug-Resistant Tuberculosis.
Furin J, Cox H. Furin J, et al. Clin Infect Dis. 2017 Oct 1;65(7):1212-1213. doi: 10.1093/cid/cix491. Clin Infect Dis. 2017. PMID: 28549086 Free PMC article. No abstract available.